Author

Matthias Pinter

Medical University of ViennaORCID 0000-0002-7260-532XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Ahmed Omar KasebiD· 1 shared Alessandro ParisiiD· 1 shared Andrea DalbeniiD· 1 shared Antonio D’AlessioiD· 1 shared Anwaar SaeediD· 1 shared Aria TorkpouriD· 1 shared Bernardo StefaniniiD· 1 shared Bernhard ScheineriD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ahmed Omar KasebORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.

Pasquale Lombardi, Erik Ramon‐Gil, Leonardo Brunetti, Giulia Francesca Manfredi, George Merces, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Aria Torkpour, Ciro Celsa, Bernardo Stefanini, Hannah Yang, Fionnuala Crowley, Thomas Urban Marron, Anwaar Saeed, Matthias Pinter, , David James Pinato

This study identifies clinical and molecular features of primary refractoriness to atezolizumab plus bevacizumab in HCC, showing poor outcomes and an immunosuppressive tumor microenvironment.

bioRxiv · Jul 8, 2025 · PreprintCancer Biology